false
0001557376
0001557376
2026-05-12
2026-05-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 12, 2026
ZEO SCIENTIFIX, INC.
(Exact name of registrant as specified in its charter)
| Nevada |
|
000-55008 |
|
47-4180540 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
3321 College Avenue, Suite 246
Davie, Florida |
|
33314 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (888) 963-7881
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class |
|
Trading Symbol |
|
Name of each exchange on which registered |
| None |
|
N/A |
|
N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this
“Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,”
“us” and “our” refer to Zeo ScientifiX, Inc.
Item 8.01 Other Events.
On May 12, 2026, ZEO issued a press release announcing
that it had achieved a significant milestone in that for the first time in Company history, ZEO’s single month unaudited sales surpassed
the $1 million mark in April 2026.
A copy of the press release is included as Exhibit
99.1 to this Report.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release, dated May 12, 2026 |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 12, 2026 |
ZEO SCIENTIFIX, INC. |
| |
|
|
| |
By: |
/s/ Ian T. Bothwell |
| |
|
Ian T. Bothwell
Chief Executive Officer and Chief Financial Officer |
Exhibit 99.1
FOR IMMEDIATE RELEASE
ZEO ScientifiX Announces That Unaudited Monthly
Sales Surpassed $1.0 million in April 2026, the first time the Company has achieved this milestone.
FORT LAUDERDALE, FL – May 12, 2026
– ZEO ScientifiX (OTCQB: ZEOX) (“ZEO” or the “Company”), a regenerative medicine products
company serving physician-run clinics across the United States, today announced that it had reached a defining commercial milestone.
For the first time in Company history, ZEO’s single month unaudited sales surpassed the $1 million mark in April 2026.
Management believes that this achievement marks a significant inflection point in ZEO’s growth trajectory and reflects the
successful execution of a physician-first commercial strategy that we believe is uniquely positioned to scale.
At the core of this momentum is the Company’s
newly implemented dedicated internal sales force. Building on this foundation, ZEO is actively looking to add additional full-time sales
professionals to accelerate physician onboarding, broaden geographic reach, and deepen penetration within existing clinic networks. As
ZEO scales its sales infrastructure, management expects physician count, revenue per account, and total Company revenue to grow in parallel.
Another significant driver of this momentum has
been ZEO’s physician education strategy, including its ongoing regenerative medicine masterclass programs. These initiatives are
designed to educate physicians and physician practices on the clinical, operational, and practice-development aspects of regenerative
medicine. Management believes this physician-first education model has helped accelerate adoption, deepen trust with clinical partners,
and support more sustainable account growth
Management Commentary
Ian Bothwell, Chief Executive Officer of ZEO
ScientifiX, said, “April’s results represent a genuine inflection point for ZEO. Physicians across the country are actively
seeking high-quality, differentiated solutions in the rapidly evolving market for regenerative medicine therapeutics, and our Company
is meeting that demand at scale. The growth we are reporting we believe is not incidental. It reflects a deliberate build, and we are
accelerating it.”
He added, “Our expanding sales force and
our physician education initiatives are operating in parallel. We are not simply moving product. We are educating physicians, supporting
practices, and helping clinicians build sustainable, high-performing regenerative medicine programs. That educational infrastructure,
including our masterclass model, is a major reason this growth is beginning to compound.”
Sean Vega-Stanton, M.S., General Manager of ZEO
ScientifiX, said, “Breaking through $1 million in a single month is not just a number. It is proof of concept. We continue to pursue
strategies to expand our physician network, and we believe the next phase of growth will be larger than what we have already achieved.
The infrastructure is in place. The market is ready. We are moving.”
About ZEO ScientifiX (OTCQB: ZEOX)
ZEO ScientifiX is a regenerative medicine
products company dedicated to advancing patient outcomes through physician-run clinics. ZEO supplies cutting-edge biologics and regenerative
therapies, partnering with clinicians to drive clinical excellence and sustainable practice growth.
Forward-Looking Statements
Certain statements contained in this press release
should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange
Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and
unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could
vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
Media Contact:
ZEO ScientifiX, Inc.
Karlista Maroney
Director of Growth Strategy
IR@zeoscientifix.com
